Ramky Infrastructure shares ended at ₹480.25, up by ₹22.20, or 4.85%, on the BSE following the announcement of a significant contract win. According to reports from CNBC TV18, the stock rose as much as ₹22.20 to ₹480.25 on Friday, reflecting strong investor confidence in the company's ability to secure large-scale infrastructure projects. The positive market response demonstrates the market's appreciation for the company's strategic expansion into high-value pharmaceutical and life sciences infrastructure.
The company secured a ₹3,000 crore order from Maharashtra Industrial Development Corporation (MIDC) through its wholly-owned subsidiary Maha Integrated Life Sciences City Limited (MILeS City). As reported by CNBC TV18, the concession agreement was executed for the development, operation, maintenance and management of a high-tech pharmaceutical park in Dighi Port Industrial Area, Mangaon and Roha Taluk, Raighad District in Maharashtra on PPP basis. The project will be executed on a Public-Private Partnership (PPP) basis under the Design, Build, Finance, Operate, and Transfer (DBFOT) model with a 95-year concession period and five-year construction phase.
The project involves the development of an industrial park spanning 1,000 hectares in Maharashtra's Raigad district, consisting of industrial zones, commercial areas, common infrastructure, utilities, internal roads, and designated open spaces. According to CNBC TV18, the pharmaceutical park will be developed across parts of Mangaon and Roha talukas and is designed to create an integrated life sciences manufacturing ecosystem with advanced infrastructure, innovation-focused R&D centres, incubation hubs, and technology transfer platforms. Under the concession agreement, MILeS City will manage development, operations, maintenance, and management for the entire concession period, generating revenue through land lease premiums, lease rentals, development and maintenance charges, and operational charges for utilities and shared facilities.
The construction portion of the project, expected to be executed in the next five years, will form part of Ramky Infrastructure's order book, taking it to around ₹13,500 crore. As reported by CNBC TV18, the project is expected to boost industrial infrastructure in the region, attract investment in the pharmaceutical and life sciences sectors, create direct and indirect employment opportunities, and stimulate growth in ancillary industries and local businesses. Sunil S Nair, CEO, Ramky Infrastructure Ltd, stated that this agreement marks a significant milestone for industrial development and wider communities, enabling pharmaceutical and biotechnology companies to grow within a well-supported and globally competitive manufacturing environment.
The company's revenue from operations showed growth of 6.49% to ₹488.92 crore in Q3 FY26 compared to ₹459.09 crore in the year-ago period. According to Upstox, this demonstrates the company's consistent revenue growth trajectory alongside its strategic expansion into new infrastructure segments through both organic growth and acquisitions. The ₹3,000 crore MIDC order represents a significant addition to the company's order book and reinforces its position in the pharmaceutical and life sciences infrastructure sector.
